This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Key PointsCormorant Asset Management sold 775,000 Arcellx shares in the fourth quarter.The fund’s quarter-end position value in Arcellx decreased by $63.63 million, reflecting a complete position sale during the period.The position previously accounted for 4.4% of the fund’s AUM in the prior quarter, making this a notable exit.10 stocks we like better than Arcellx › On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filin…